30-05-2012: The largest ever genomic study of relapsed acute lymphoblastic leukaemia (ALL) will fund Population Genetics Technologies Ltd to identify the genetic factors in resistance to treatment by carrying out a multi-year analysis of thousands of DNA samples from relapsed ALL cases.
The IntReALL consortium of 23 research teams, led by Vaskar Saha, Professor of Paediatric Oncology at The University of Manchester, will gather DNA across Europe, Japan, Israel and Australia from children who have relapsed after treatment for ALL. With funding from IntReALL’s EU FP7 grant Population Genetics, creator of innovative methods for population-scale genetic analyses and biomarker discovery, will study the resulting biobank using its GenomePooling™ workflows to identify and validate associations between genetic risk factors and treatment efficacy.
Goals are to understand which patients are suited for reduced toxicity treatments and also to provide a genetically stratified basis for randomised controlled studies of potential new treatment agents.
Explained Professor Vaskar Saha: “This study presents a unique but highly complex opportunity to interrogate a large dataset of this malignant disease. Population Genetics has shown its expertise in the field of large population gene association studies which would probably otherwise be too costly and error-prone for clinical researchers seeking to test hypotheses”.
Alan Schafer, CEO of Population Genetics, commented: “We are pleased to be working with the IntReALL consortium on this important multi-year study which will allow us to demonstrate that our population-scale association study techniques can be applied to complex solid lymph node tumours, in addition to the other areas of disease genetics in which we currently work”.
Two research groups at the University of Oxford will use Population Genetics Technologies to enable studies on gene variants associated with myocardial infarction, diabetes and metabolic disease. The company has signed a collaboration agreement with the University of Oxford to provide unive ... more
The largest ever genomic study of relapsed acute lymphoblastic leukaemia (ALL) will fund Population Genetics Technologies Ltd to identify the genetic factors in resistance to treatment by carrying out a multi-year analysis of thousands of DNA samples from relapsed ALL cases.The IntReALL con ... more
Population Genetics Technologies Ltd. has appointed Alan Schafer, PhD to the post of Chief Executive Officer. Schafer brings deep experience in research, “big pharma” management and building new businesses. He is Adjunct Professor of Innovation at Imperial College London Business School and ... more
With mathematical methods and computer simulations, Humboldt Fellow Richard Henchman (University of Manchester) is exploring the factors of protein stability – Research stay at the Heidelberg Institute for Theoretical Studies (HITS), supported by the Alexander von Humboldt foundation.
Since ... more
Scientists have used sugar-coated scaffolding to move a step closer to the routine use of stem cells in the clinic and unlock their huge potential to cure diseases from Alzheimer's to diabetes.
The problem facing scientists is how to encourage stem cells to turn into the particular type of ... more
UK scientists have designed a high throughput method to determine the phenotypes of the different Escherichia coli strains that cause urinary tract infections. The method couples bacterial growth requirements to Fourier transform infrared spectroscopy. The majority of urinary tract infectio ... more